Loading
A phase 1/2 trial of BNT317 DL1 in advanced solid tumours, run by BioNTech SE, now recruiting.
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06750185 by BioNTech SE, with 248 participants planned, started 2025-01-13 and due to reach its primary completion in 2031-04. Interventions recorded: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5 and BNT317 DL6.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/